Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AC Immune SA (ACIU)
Price$2.86Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF3.6M | CHF27.3M | CHF14.8M | CHF3.9M | CHF0 | CHF15.4M | CHF110.5M | CHF6.9M | CHF20.3M | CHF23.2M | CHF39.1M |
| Research & development | CHF56.4M | CHF62.6M | CHF54.6M | CHF60.3M | CHF62.3M | CHF59.5M | CHF50.4M | CHF44.3M | CHF32.7M | CHF25.8M | CHF17.0M |
| Operating expenses | CHF72.9M | CHF79.7M | CHF68.4M | CHF74.8M | CHF79.0M | CHF76.7M | CHF65.9M | CHF56.5M | CHF42.8M | CHF33.7M | CHF20.5M |
| Operating income | −CHF69.3M | −CHF52.4M | −CHF53.6M | −CHF70.8M | −CHF79.0M | −CHF61.3M | CHF44.5M | −CHF49.5M | −CHF22.5M | −CHF10.5M | CHF18.6M |
| Operating margin | −1,940.05% | −191.80% | −362.30% | −1,800.43% | — | −396.99% | 40.32% | −716.87% | −111.28% | −45.04% | 47.64% |
| EBITDA | −CHF67.8M | −CHF48.6M | −CHF51.8M | −CHF68.0M | — | — | — | — | −CHF22.0M | −CHF10.2M | CHF18.9M |
| EBITDA margin | −1,896.25% | −178.03% | −350.19% | −1,728.74% | — | — | — | — | −108.41% | −43.84% | 48.38% |
| Net income | −CHF70.4M | −CHF50.9M | −CHF54.2M | −CHF70.8M | −CHF73.0M | −CHF61.9M | CHF45.4M | −CHF51.0M | −CHF26.4M | −CHF7.1M | CHF20.3M |
| Net profit margin | −1,971.65% | −186.44% | −366.41% | −1,798.04% | — | −401.28% | 41.14% | −737.14% | −130.39% | −30.57% | 51.85% |
| Basic EPSper basic share | -CHF 0.70 | -CHF 0.51 | -CHF 0.64 | -CHF 0.85 | -CHF 0.97 | -CHF 0.86 | CHF 0.64 | -CHF 0.82 | -CHF 0.46 | -CHF 0.14 | CHF 0.47 |
| Diluted EPSper diluted share | -CHF 0.70 | -CHF 0.51 | -CHF 0.64 | -CHF 0.85 | -CHF 0.97 | -CHF 0.86 | CHF 0.64 | -CHF 0.82 | -CHF 0.46 | -CHF 0.14 | CHF 0.44 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BVF INC/IL | 19.82M |
Pfeifer Andrea | 3.83M |
WELLS FARGO & COMPANY/MN | 1M |
RENAISSANCE TECHNOLOGIES LLC | 840.13K |
MILLENNIUM MANAGEMENT LLC | 773.59K |
BlackRock, Inc. | 519.27K |
DIMENSIONAL FUND ADVISORS LP | 340.08K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 232.95K |
CITADEL ADVISORS LLC | 207.61K |
Roberts Christopher James | 155.38K |
Donati Piergiorgio | 141.12K |
MORGAN STANLEY | 131.82K |
TWO SIGMA INVESTMENTS, LP | 102.83K |
Twyman Roy Ervin | 92.56K |
Qube Research & Technologies Ltd | 92.35K |
UBS Group AG | 85.61K |
Buetler Monika | 71.66K |
Zuegel Martin | 71.41K |
June Carl Howard | 67.56K |
GEODE CAPITAL MANAGEMENT, LLC | 61.85K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 15, 2026Form 4 · 10b5-1 | Pfeifer AndreaChief Executive Officer | SellCommon Share | 10.0K | $2.79 | $27.9K | 3.82M |
| Apr 15, 2026Form 4/A · 10b5-1 | Pfeifer AndreaChief Executive Officer | SellShare | 10.0K | $3.14 | $31.4K | 3.83M |
| Apr 15, 2026Form 4 · 10b5-1 | Pfeifer AndreaChief Executive Officer | BuyShare | 10.0K | $3.14 | $31.4K | 3.83M |